African countries receive over 29 million Covid-19 vaccine doses


'The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA),' Pfizer and BioNTech said in a joint statement.

A preprint with The Lancet, the research found those people who previously had natural Covid-19 infection had a peak antibody response after just one Pfizer vaccination.

Africa CDC, the specialized healthcare agency of the African Union (AU), said as of Thursday, a total of over 29.1 million vaccine doses have been acquired by African countries, with approximately 10.3 million doses having been administered.

"It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up", BioNTech CEO Ugur Sahin said. "For domestic travel, fully vaccinated people do not need to get a COVID-19 test before or after travel and do not need self-quarantine after travel", says CDC Director Dr. Rochelle Walensky.

It comes as a separate UK-based study found the Pfizer vaccine produces an "off the scale" immune response that is likely to protect against the Brazilian variant of Covid-19, with scientists in the United Kingdom reporting strong immune responses in older people who had received two shots of the Pfizer vaccine.

The companies said the results contained data on more than 12,000 participants who had been fully inoculated for at least six months.

'The vaccine elicits such high levels of antibodies that even when confronted with a variant. there's still meaningful protection, ' Hensley told CNN.

"The antibody levels were so high that they'd gone above the thresholds so they had to dilute them". As part of the process, they both must continue their clinical trials for two years and will continue to report safety and efficacy data as they get it.